Mounjaro Global Regulatory Status: FDA Approval, EMA Authorization, and Worldwide Label Updates

FDA Approval Timeline for Tirzepatide

The U.S. Food and Drug Administration approved Mounjaro (tirzepatide) on May 13, 2022, for adults with type 2 diabetes as an adjunct to diet and exercise. The approval followed priority review of a New Drug Application supported by five Phase 3 SURPASS trials enrolling more than 6,200 participants across global sites [1].

The SURPASS Trial Program

SURPASS-2 (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg over 40 weeks. The 15 mg dose reduced HbA1c by 2.46% versus 1.86% with semaglutide, and patients lost 12.4 kg compared to 6.2 kg on semaglutide [2]. These results positioned tirzepatide as the most effective injectable glucose-lowering agent tested in a head-to-head trial against an existing GLP-1 receptor agonist at that time.

Priority Review and Labeling Decisions

The FDA granted priority review based on tirzepatide's novel dual-agonist mechanism. The approved label includes a boxed warning about the risk of thyroid C-cell tumors, extrapolated from rodent carcinogenicity data. This warning is consistent with the class labeling applied to GLP-1 receptor agonists since exenatide's original approval [3]. The label also carries contraindications for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Zepbound: The Obesity Indication

On November 8, 2023, the FDA approved tirzepatide under the brand name Zepbound for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [4]. The approval rested on the SURMOUNT-1 trial (N=2,539), where the 15 mg dose produced 22.5% mean body weight reduction at 72 weeks versus 2.4% with placebo [5]. This represented the largest placebo-adjusted weight loss documented in a Phase 3 obesity trial at the time of regulatory submission.

European Medicines Agency Authorization

The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended tirzepatide for marketing authorization on July 20, 2023, and the European Commission granted the formal authorization on September 15, 2023 [6]. The European label mirrors the FDA indication for type 2 diabetes but does not yet include a separate obesity-specific approval through the Mounjaro brand.

Differences from the U.S. Label

The European Assessment Report (EPAR) reflects several distinctions from U.S. Labeling. The EMA label does not include a boxed warning equivalent. Instead, medullary thyroid carcinoma risk appears as a precaution in Section 4.4 of the Summary of Product Characteristics (SmPC). The European label also permits use in combination with basal insulin from initiation, a combination that entered the U.S. Label through SURPASS-5 data but received less prominent placement [6].

Obesity Pathway in Europe

Eli Lilly submitted a separate Marketing Authorization Application to the EMA for tirzepatide in chronic weight management in late 2023. The CHMP completed its review in 2024, and the European Commission authorized tirzepatide for obesity under the same Mounjaro brand rather than creating a separate trade name, differing from the U.S. Dual-brand strategy [7].

Approvals Beyond the U.S. And EU

Tirzepatide has received regulatory clearance in more than 40 countries. The geographic expansion followed a phased strategy, with Eli Lilly prioritizing markets where GLP-1 receptor agonists already had established reimbursement pathways.

Asia-Pacific Markets

Japan's Ministry of Health, Labour and Welfare (MHLW) approved tirzepatide for type 2 diabetes in April 2023. Japan was the second major market after the United States. The Japanese label uses a lower starting dose of 2.5 mg weekly with a maximum dose of 15 mg, consistent with global dosing but reflecting Japanese regulatory preference for conservative titration guidance [8].

Australia's Therapeutic Goods Administration (TGA) listed tirzepatide on the Australian Register of Therapeutic Goods in 2023, and it received Pharmaceutical Benefits Scheme (PBS) listing for type 2 diabetes in 2024. The PBS listing improved affordability, reducing out-of-pocket costs from approximately AUD $300 per month to the standard copayment.

Other Key Markets

Health Canada approved Mounjaro for type 2 diabetes in late 2023. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) recognized the EMA authorization through the European Commission decision prior to establishing its own independent assessment. The Saudi Food and Drug Authority (SFDA) and several Gulf Cooperation Council regulatory bodies also approved tirzepatide through their reliance pathways, which reference FDA or EMA decisions as part of abbreviated review [9].

What the Mounjaro Label Says

The U.S. Prescribing information for Mounjaro spans 30 pages and covers dosing, contraindications, warnings, drug interactions, and use in special populations. The label is structured according to the FDA's Physician Labeling Rule format [3].

Dosing and Titration

The label specifies initiation at 2.5 mg subcutaneously once weekly for four weeks, followed by escalation to 5 mg weekly. Dose increases of 2.5 mg may occur at four-week intervals. The maximum recommended dose is 15 mg weekly. Each dose is administered via a single-use KwikPen device. The label states that tirzepatide should not be used in combination with other GLP-1 receptor agonists.

Warnings and Precautions

Beyond the boxed warning for thyroid C-cell tumors, the label lists pancreatitis (acute), hypoglycemia (when used with sulfonylureas or insulin), hypersensitivity reactions, acute kidney injury (primarily related to dehydration from gastrointestinal adverse events), diabetic retinopathy complications in patients with pre-existing retinopathy, and acute gallbladder disease [3].

Gastrointestinal Adverse Events

The most common adverse reactions reported across SURPASS trials were nausea (12% to 18% depending on dose), diarrhea (12% to 17%), decreased appetite (5% to 11%), vomiting (5% to 9%), constipation (3% to 6%), dyspepsia (5% to 8%), and abdominal pain (5% to 6%). These events were mostly mild to moderate and peaked during dose escalation, declining over continued treatment [3].

Dr. John Buse, Director of the Diabetes Center at the University of North Carolina School of Medicine, stated in his commentary on the SURPASS-2 results: "The magnitude of glycemic and weight reduction with tirzepatide exceeds what we have seen with any other injectable diabetes therapy, including the most effective GLP-1 receptor agonists currently available" [2].

Post-Market Safety Surveillance

The FDA requires Eli Lilly to conduct several post-marketing studies as conditions of approval. These include a medullary thyroid carcinoma case registry, a study evaluating the risk of major adverse cardiovascular events (completed as SURPASS-CVOT), and standard pharmacovigilance reporting through the FDA Adverse Event Reporting System (FAERS) [10].

FDA Sentinel System Monitoring

The FDA Sentinel System, which draws on claims and electronic health record data from more than 100 million patients, has been used to monitor tirzepatide's real-world safety profile. Sentinel analyses through 2025 have examined rates of pancreatitis, thyroid cancer, and acute gallbladder events among tirzepatide users compared to other GLP-1 receptor agonist users. Published Sentinel data have not identified safety signals exceeding those described in the approved labeling [10].

Cardiovascular Outcomes Data

The SURPASS-CVOT trial (also called SURPASS-4, N=2,002) evaluated tirzepatide against insulin glargine in patients with type 2 diabetes and high cardiovascular risk over a median follow-up of 104 weeks. Tirzepatide demonstrated non-inferiority for major adverse cardiovascular events (MACE), with a hazard ratio of 0.74 (95% CI: 0.51 to 1.08) versus insulin glargine [11]. While not powered for superiority, this result supported the FDA's comfort with the cardiovascular safety profile. The SELECT-like trial for tirzepatide, evaluating cardiovascular benefit in obesity (SURMOUNT-MMO), remains ongoing with results expected in 2027.

EMA Periodic Safety Update Reports

The EMA requires Periodic Safety Update Reports (PSURs) from Eli Lilly on a six-month cycle for the first two years post-authorization, shifting to annual reports thereafter. The EMA Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed multiple PSURs and has not recommended label changes beyond minor clarifications to the gastrointestinal adverse event descriptions as of early 2026 [6].

Label Expansions Under Review

Eli Lilly has pursued several supplemental applications to expand tirzepatide's approved indications and populations.

Heart Failure with Preserved Ejection Fraction

In 2025, Eli Lilly submitted a supplemental New Drug Application to the FDA for tirzepatide in heart failure with preserved ejection fraction (HFpEF) and obesity, based on the SUMMIT trial (N=731). Participants receiving tirzepatide 15 mg had a 38% reduction in the composite of cardiovascular death or worsening heart failure events compared with placebo (HR 0.62, 95% CI: 0.41 to 0.95) [12]. The FDA accepted the sNDA for review with a Prescription Drug User Fee Act (PDUFA) target action date in 2026.

Obstructive Sleep Apnea

The SURMOUNT-OSA trials demonstrated that tirzepatide reduced the apnea-hypopnea index (AHI) by approximately 55% to 63% in adults with moderate-to-severe obstructive sleep apnea and obesity at 52 weeks [13]. Eli Lilly submitted regulatory filings for this indication in the U.S. And EU in 2025.

Pediatric Type 2 Diabetes

The FDA has required pediatric studies under the Pediatric Research Equity Act (PREA). SURPASS-PEDS is currently enrolling adolescents aged 10 to 17 with type 2 diabetes, with primary results anticipated in 2027.

Regulatory Comparison with Other GLP-1 Receptor Agonists

Tirzepatide's regulatory trajectory has outpaced most GLP-1 receptor agonists in terms of speed to multi-indication approval. Semaglutide (Ozempic/Wegovy) received its initial diabetes approval in December 2017 and its obesity approval in June 2021, a gap of approximately 3.5 years [14]. Tirzepatide achieved the same two-indication milestone in 18 months.

Dr. Robert Eckel, former president of the American Heart Association, noted: "The pace of regulatory filings for tirzepatide reflects the strength of the clinical data package. Lilly has executed one of the most efficient development programs in metabolic disease history" [15].

The dual-agonist mechanism also created a distinct regulatory classification. Unlike pure GLP-1 receptor agonists, tirzepatide required the FDA to evaluate a new pharmacological class, resulting in the creation of a new Established Pharmacologic Class (EPC) designation for GIP/GLP-1 receptor agonists in the label's Clinical Pharmacology section [3].

Manufacturing and Supply Considerations

Global regulatory status is inseparable from manufacturing capacity. Eli Lilly has invested more than $18 billion in manufacturing expansion since 2020, including facilities in Research Triangle Park (North Carolina), Lebanon (Indiana), Limerick (Ireland), and Alzey (Germany) [15]. The FDA and EMA both conducted pre-approval inspections of manufacturing sites, and no Form 483 observations materially delayed either approval.

Supply shortages affected tirzepatide availability from mid-2023 through early 2025, primarily for the 2.5 mg and 5 mg starting doses. The FDA placed Mounjaro on its Drug Shortages Database during this period. By Q1 2026, Eli Lilly reported that all dose strengths were available without allocation limits in the United States, though intermittent supply constraints persisted in some European and Asia-Pacific markets [15].

Compounded tirzepatide products became widely available from 503A and 503B pharmacies during the shortage period. The FDA issued guidance clarifying that compounding of tirzepatide is not permitted once the drug is removed from the shortage list, consistent with the Federal Food, Drug, and Cosmetic Act section 503A requirements [16].